UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Suspected Staphylococcus aureus skin and soft tissue infections: Evaluation and management in neonates

Author
Sheldon L Kaplan, MD
Section Editor
Morven S Edwards, MD
Deputy Editor
Mary M Torchia, MD

INTRODUCTION

The evaluation and management of suspected methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections (SSTI) in neonates (≤28 days of age) will be reviewed here. General aspects of the management of SSTI; the evaluation and management of MRSA SSTI in children older than 28 days; the epidemiology, prevention, and control of MRSA infections in children; and the treatment of invasive MRSA infections in children are discussed separately.

(See "Cellulitis and erysipelas".)

(See "Impetigo".)

(See "Infectious folliculitis".)

(See "Skin abscesses, furuncles, and carbuncles".)

              

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Thu Sep 01 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.
  2. American Academy of Pediatrics. Staphylococcal infections. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, 2015. p.715.
  3. Fortunov RM, Hulten KG, Hammerman WA, et al. Evaluation and treatment of community-acquired Staphylococcus aureus infections in term and late-preterm previously healthy neonates. Pediatrics 2007; 120:937.
  4. Miller LG, Perdreau-Remington F, Bayer AS, et al. Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation. Clin Infect Dis 2007; 44:471.
  5. Day CT, Kaplan SL, Mason EO, Hulten KG. Community-associated Staphylococcus aureus infections in otherwise healthy infants less than 60 days old. Pediatr Infect Dis J 2014; 33:98.
  6. Autret E, Laugier J, Marimbu J, et al. [Comparison of plasma levels of amoxicillin administered by oral and intravenous routes in neonatal bacterial colonization]. Arch Fr Pediatr 1988; 45:679.
  7. Boothman R, Kerr MM, Marshall MJ, Burland WL. Absorption and excretion of cephalexin by the newborn infant. Arch Dis Child 1973; 48:147.
  8. Gorwitz RJ. A review of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Pediatr Infect Dis J 2008; 27:1.